Prescription drug costs remain one of the most difficult expenses for Medicaid payers to forecast and manage. As federal policymakers explore most-favored-nation drug pricing, health plan executives need to understand how international price benchmarks could influence pharmacy spending and utilization assumptions.
The Centers for Medicare & Medicaid Services’ GENEROUS Model introduces a new approach to reducing Medicaid prescription drug costs through supplemental manufacturer rebates. In this video, TOG Network Solutions examines what the model could mean for payer financial planning and why health plans should prepare for both its potential savings and its operational implications.